AZACTAM INJ *
AZACTAM INJ *
Azetreonam 500mg vial inj,
List of Related Indications:
- Urinary tract infections- UTI
List Of Drugs:
- Aztreonam- @ - Monobactams-(Nov 2002)
Indication Type Description:
Dosages/ Overdosage Etc
Pregnancy and lactation
Interacting drugs- summary
concomittant administration causes clinically insignificant increases in aztreonam Furosemide levels
(eg. cefoxitin, imipenem ) induce high levels of Beta- lactamase in vitro in some gram-negative aerobes such as Enterobacter and Psuedomonas species resulting in antagonism to many Beta lactum antibiotics including aztreonam. Beta-lactanase-inducing antibiotics should not be used concomittantly with aztreonam
Urinary tract infections Lower respiratory tract infections Septicemia Skin and skin structure infections Intra-abdominal infections Gynaecologic infections
Local- phlebitis/thromophlebitis, following Iv administration,discomfort/swelling at the injection site following IM administration.
Hematologic- pancytopenia, neutropenia, thrombocutopenia, anemia, leukocytosis, thrombocytosis
GI- diarrhea, nausea, vomiting, abdominal cramps, GI bleeding Dermtologic- rash, purpura, erythema mutiforme, urticaria, exfoliative dermatisis, petechiae, pruritus, diaphoresis
Cardiovascular - transcient ECG changes, (ventricular bigminy and PVC ) hypotension. Hepatic- hepatitis, jaundice
CNS- seizure, confusion, headache, vertigo, paresthesia, insomnia, diziness.
Special senses- tinnitus, diplopia, mouth ulcer, alterd taste, numb tongue, sneezing, nasal congeston, halitosis
Miscellaneous- vaginal candidiasis, vaginitis, breast tenderness, weakness, muscular aches, fever, malaise, anaphylaxis, flushing, chaest pain, dyspnea.
Lab test abnormalities- Elevation of AST, ALT, and alkaline phosphatase, increase in prothrombin times, eosinophillia, positive Coombs test,and serum creatinine.
Hypersensitivity to Aztreonam
Superinfection- use ofantibiotics (especially prolonged or repeated therapy) may result in bacterial ( including gram-positive S aureus and S faecalis ) or fungal overgrowth of nonsuceptible organisms. Such overgrowth may lead to a secondaryinfection. Take appropiate measures if superinfection occurs.
Monitor patients who have had immediate hypersensitivity reactions (eg.anphylactic or urticarial ) to penicillins or cephalosprins. If an allergic raection to aztreonam occurs, doscontinue the drug and institute supportive treatment.
Renal/hepatic function impairment- appropitae monitoring is recommended. If an aminoglycoside is used concurrently with aztreonam ,especially if high doses of the former are used or if therapy is prolonged, monitor renal function because of potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics.
Pregnancy- Use during pregnancy only if clearly needed.
Lactation- Consider temporary discontinuation of nursing.
Children- Safey and efficacy for use in children is not established.
Dosages/ Overdosage Etc:
Urinary tract infections
Dosage: Give IM or IV. Individualise dosage. 500 mg or 1g 8 or 12 hours
Children- 30mg/kg every 6 to 8 hours has been used in children for various infections
Azetreonam,a synthetic bactericidal antibiotic, is the first of a new class of antibiotics identified as monmobactams. The monobactums have a monocyclic Beta-lactum nucleus and are structurally different from Beta-lactums (eg. penicillins, cephalosporins, cephamycin). Aztreonam has a wide range of spectrum of activity against gram-negative aerobic pathogens. The bactericidal action results from the inhibition of bacterial cell wall synthesis due to a high affinity of aztreonam for penicillin binding protein 3 (PBP3).
Following a single IM injection of 500mfg an 1g maximun serum concentration occur at about 1 hour. The serum half-life averaged 1.7 hrs in subjects with normal renal function, independent of the dose and the route. The average elimination half-life appears slightly longer in healthy males. In patients with impaired renal function,the serum half-life is prolonged.
Pregnancy and lactation:
Use during pregnancy only if clearly needed.
Consider temporary discontinuation of nursing.
Safey and efficacy for uee in children is not established.